Received May 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| MNQ | MENINGOCOCCAL CONJUGATE (MENVEO) | NOVARTIS VACCINES AND DIAGNOSTICS | 2 | AMVB030A | — |
administration of the lyophilized component of Menveo with sterile water diluent; administration of the lyophilized component of Menveo with sterile water diluent; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of wrong solution used in drug reconstitution in a 17-year-old female patient who received Men ACWY-CRM NVS (Menveo) (batch number AMVB030A, expiry date 30-APR-2025) for prophylaxis. Previously administered products included Menveo (received first dose of Menveo on an unknown date). On 30-APR-2025, the patient received the 2nd dose of Menveo. On 30-APR-2025, an unknown time after receiving Menveo, the patient experienced wrong solution used in drug reconstitution (Verbatim: administration of the lyophilized component of Menveo with sterile water diluent) and inappropriate dose of vaccine administered (Verbatim: administration of the lyophilized component of Menveo with sterile water diluent). The outcome of the wrong solution used in drug reconstitution and inappropriate dose of vaccine administered were not applicable. Additional Information: GSK Receipt Date: 30-APR-2025 The pharmacist reported about the administration of the lyophilized component of Menveo with sterile water diluent which led to wrong solution used in drug reconstitution and inappropriate dose of vaccine administered. They mentioned the dose was administered on the day of reporting and being the second dose. The Vaccine Administration Facility was the same as Primary Reporter